Rakuten Medical, Inc.
StreetZero Signal 77
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing its Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world.
LATEST FUNDINGPrivate Placement
$9.0M
Announced 2026-10-06
TOTAL RAISED$991M
IN THE NEWS
- 🔗 Rakuten Medical Raises $100 Million in Oversubscribed Series F to Accelerate Development Toward U.S. Regulatory Approval
- 🔗 Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform - Rakuten Medical - To conquer cancer.
- 🔗 Rakuten Medical Valuation, Funding & Investors | Multiples
- 🔗 Rakuten Medical Raises $100 Million in Oversubscribed Series F to Accelerate Development Toward U.S. Regulatory Approval - Rakuten Medical - To conquer cancer.
- 🔗 Rakuten Medical, Inc. Closes $166 Million Series D Financing led by General Catalyst - Rakuten Medical - To conquer cancer.
EMPLOYEES—
FOUNDED—
HQSan Diego, CA, USA
Industry
Biotechnology
Tags
BiotechnologyPhotoimmunotherapyOncology
Investors
Key highlights
- Raised $100M in oversubscribed Series F to advance U.S. regulatory approval.
- Closed $119M Series E to develop Alluminox platform.
- Completed $166M Series D led by General Catalyst.
- Originally known as Aspyrian Therapeutics with Series A in 2015.
- Photoimmunotherapy platform induces rapid selective cell killing in pre-clinical studies.
Ask StreetZero about Rakuten Medical, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account